References
- Scannell JW, Blanckley A, Boldon H and Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11, 191-200 https://doi.org/10.1038/nrd3681
- International Council of Harmonization (ICH) Guidelines (2005) The non-clinical evaluation of the potential for delayed ventricular repolarization (Qt Interval Prolongation) by human pharmaceuticals. S7B (https://database.ich.org/sites/default/files/S7B_Guideline.pdf)
- International Council of Harmonization (ICH) Guidelines (2006) The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. E14 4 (https://database.ich.org/sites/default/files/E14_Guideline.pdf)
- Hoffmann P and Warner B (2006) Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 53, 87-105 https://doi.org/10.1016/j.vascn.2005.07.003
- Guo L, Coyle L, Abrams RM, Kemper R, Chiao ET and Kolaja KL (2013) Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci 136, 581-594 https://doi.org/10.1093/toxsci/kft205
- Mercola M, Colas A and Willems E (2013) Induced pluripotent stem cells in cardiovascular drug discovery. Circ Res 112, 534-548 https://doi.org/10.1161/CIRCRESAHA.111.250266
- Suter-Dick L, Alves PM, Blaauboer BJ et al (2015) Stem cell-derived systems in toxicology assessment. Stem Cells Dev 24, 1284-1296 https://doi.org/10.1089/scd.2014.0540
- Palpant NJ, Pabon L, Friedman CE et al (2017) Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells. Nat Protoc 12, 15-31 https://doi.org/10.1038/nprot.2016.153
- Ronaldson-Bouchard K, Ma SP, Yeager K et al (2018) Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature 556, 239-243 https://doi.org/10.1038/s41586-018-0016-3
- Sirenko O, Cromwell EF, Crittenden C, Wignall JA, Wright FA and Rusyn I (2013) Assessment of beating parameters in human induced pluripotent stem cells enables quantiative in vitro screening for cardiotoxicity. Toxicol Appl Pharmacol 273, 500-507 https://doi.org/10.1016/j.taap.2013.09.017
- Blinova K, Dang Q, Millard D et al (2018) International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. Cell Rep 24, 3582-3592 https://doi.org/10.1016/j.celrep.2018.08.079
- Millard D, Dang Q, Shi H et al (2018) Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study. Toxicol Sci 164, 550-562 https://doi.org/10.1093/toxsci/kfy110
- Takasuna K, Asakura K, Araki S et al (2017) Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative. J Pharmacol Toxicol Methods 83, 42-54 https://doi.org/10.1016/j.vascn.2016.09.004
- Magdy T, Schuldt AJT, Wu JC, Bernstein D and Burridge PW (2018) Human Induced Pluripotent Stem Cell (hiPSC)- Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems. Annu Rev Pharmacol Toxicol 58, 83-103 https://doi.org/10.1146/annurev-pharmtox-010617-053110
- Burridge PW, Li YF, Matsa E et al (2016) Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicininduced cardiotoxicity. Nat Med 22, 547-556 https://doi.org/10.1038/nm.4087
- Burridge PW, Matsa E, Shukla P et al (2014) Chemically defined generation of human cardiomyocytes. Nat Methods 11, 855-860 https://doi.org/10.1038/nmeth.2999
- Lian X, Hsiao C, Wilson G et al (2012) Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 109, E1848-1857 https://doi.org/10.1073/pnas.1200250109
- Minami I, Yamada K, Otsuji TG et al (2012) A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xenofree conditions. Cell Rep 2, 1448-1460 https://doi.org/10.1016/j.celrep.2012.09.015
- Vandenberk B, Vandael E, Robyns T et al (2016) Which QT Correction Formulae to Use for QT Monitoring? J Am Heart Assoc 5, e003264 https://doi.org/10.1161/JAHA.116.003264
- Sagie A, Larson MG, Goldberg RJ, Bengtson JR and Levy D (1992) An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 70, 797-801 https://doi.org/10.1016/0002-9149(92)90562-D
- Park SJ, Bae D, Moon SH and Chung HM (2013) Modification of a purification and expansion method for human embryonic stem cell-derived cardiomyocytes. Cardiology 124, 139-150 https://doi.org/10.1159/000346390
- Lee JY, Kim MY, Shin SH et al (2017) Persicarin isolated from Oenanthe javanica protects against diabetes-induced oxidative stress and inflammation in the liver of streptozotocin-induced type 1 diabetic mice. Exp Ther Med 13, 1194-1202 https://doi.org/10.3892/etm.2017.4113
- Songbo M, Lang H, Xinyong C, Bin X, Ping Z and Liang S (2019) Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett 307, 41-48 https://doi.org/10.1016/j.toxlet.2019.02.013
- Ayala A, Munoz MF and Arguelles S (2014) Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014, 360438 https://doi.org/10.1155/2014/360438
- Janssen M, Koster JF, Bos E and de Jong JW (1993) Malondialdehyde and glutathione production in isolated perfused human and rat hearts. Circ Res 73, 681-688 https://doi.org/10.1161/01.RES.73.4.681
- Singh Y, Hall GL and Miller MG (1992) Species differences in membrane susceptibility to lipid peroxidation. J Biochem Toxicol 7, 97-105 https://doi.org/10.1002/jbt.2570070207
- Ruzsnavszky F, Hegyi B, Kistamas K et al (2014) Asynchronous activation of calcium and potassium currents by isoproterenol in canine ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 387, 457-467 https://doi.org/10.1007/s00210-014-0964-6